# Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck

> **NCT04129320** · PHASE2,PHASE3 · WITHDRAWN · sponsor: **MacroGenics**

## Conditions studied

- Head and Neck Cancer
- Squamous Cell Carcinoma of Head and Neck

## Interventions

- **BIOLOGICAL:** enoblituzumab
- **BIOLOGICAL:** MGA012
- **BIOLOGICAL:** MGD013

## Key facts

- **NCT ID:** NCT04129320
- **Lead sponsor:** MacroGenics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-10
- **Primary completion:** 2020-10
- **Final completion:** 2022-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Change in study design
- **Last updated:** 2022-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04129320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04129320, "Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04129320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*